An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2019
Price : $35 *
At a glance
- Drugs Cinacalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 12 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.